Drug Price Trends for NDC 69102-0150

Average Pharmacy Cost for 69102-0150

Drug Name	NDC	Price/Unit ($)	Unit	Date
SUBVENITE 150 MG TABLET	69102-0150-06	0.06504	EACH	2026-03-18
SUBVENITE 150 MG TABLET	69102-0150-06	0.06466	EACH	2026-02-18
SUBVENITE 150 MG TABLET	69102-0150-06	0.06777	EACH	2026-01-21
SUBVENITE 150 MG TABLET	69102-0150-06	0.06625	EACH	2025-12-17
SUBVENITE 150 MG TABLET	69102-0150-06	0.06544	EACH	2025-11-19

Best Wholesale Price for NDC 69102-0150

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Lexicon Pharmaceuticals' QWO® (Collagenase Clostridium Histolyticum) Market Landscape and Price Projections

Last updated: February 18, 2026

Lexicon Pharmaceuticals' QWO® (collagenase clostridium histolyticum) is approved for the treatment of moderate to severe cellulite in adult women. This analysis examines the current market for cellulite treatments, QWO®'s competitive positioning, and projects future market dynamics and pricing.

What is the Current Market for Cellulite Treatments?

The global aesthetic dermatology market, which includes cellulite treatments, is substantial and growing. Cellulite affects an estimated 85% to 90% of post-pubertal women, creating a significant demand for effective solutions. The market is segmented by treatment type, including minimally invasive procedures and topical creams.

Prior to QWO®, treatment options were primarily non-pharmacological. These included:

• Energy-based devices: Radiofrequency, laser, and ultrasound therapies aim to stimulate collagen production and improve skin texture. These treatments typically require multiple sessions and can yield variable results.
• Injectable fillers: Hyaluronic acid-based fillers can temporarily improve the appearance of cellulite by smoothing the skin surface, but do not address the underlying cause.
• Subcision devices: These devices physically cut the fibrous septa that tether the skin, creating dimples.
• Topical creams and lotions: These products often contain ingredients like caffeine, retinol, and botanical extracts, but their efficacy is generally limited to temporary skin surface improvements.

The market is characterized by a demand for treatments that offer noticeable, long-lasting results with minimal downtime. Patient satisfaction remains a key driver, alongside physician recommendations and cost-effectiveness.

How is QWO® Positioned in the Cellulite Treatment Market?

QWO® is the first and only FDA-approved injectable treatment specifically indicated for moderate to severe cellulite in women. Its mechanism of action directly targets the fibrous septa responsible for dimpling. The active pharmaceutical ingredient, collagenase clostridium histolyticum, is an enzyme that enzymatically targets and degrades collagen types I and III, the primary components of the fibrous septae [1].

Key differentiators for QWO® include:

• Pharmacological mechanism: Unlike energy-based devices or fillers, QWO® directly breaks down the structural cause of cellulite dimples.
• FDA approval: This provides a level of validated efficacy and safety compared to unapproved or off-label treatments.
• Targeted indication: QWO® is approved for moderate to severe cellulite, differentiating it from treatments aimed at milder forms or general skin rejuvenation.

However, QWO® faces competition from established non-pharmacological modalities and the potential for new entrants with alternative technologies. The complexity of cellulite, involving fat herniation, skin laxity, and the underlying fibrous septa, means that no single treatment may be universally effective.

What are the Efficacy and Safety Profiles of QWO®?

QWO®'s efficacy is demonstrated through clinical trials assessing the improvement of cellulite appearance. The primary endpoints in pivotal trials, as reported by the FDA, focused on the percentage of subjects achieving at least a one-grade improvement in cellulite severity using a validated cellulite severity scale [1].

Key Efficacy Findings (from clinical trials):

• Significant Improvement: A substantial percentage of subjects treated with QWO® showed improvement in cellulite severity compared to placebo. For example, in the pivotal Phase 3 Motion study, a statistically significant proportion of subjects receiving QWO® achieved at least a one-grade improvement on the Investigator's Global Assessment (IGA) scale at the final assessment visit [1].
• Number of Treatments: The treatment involves a series of injections administered by a healthcare professional, typically over a course of up to three treatment sessions, spaced at least 21 days apart [1].

Safety Profile:

• Common Adverse Events: The most frequently observed adverse events are injection site reactions. These include bruising, pain, redness, and swelling at the injection site [1].
• Severity of Bruising: Significant bruising is a notable side effect that has been reported. The duration and intensity of bruising can vary among patients and may influence patient adherence and satisfaction.
• Other Adverse Reactions: Less common adverse events may include itching, nodules, and discoloration at the injection site.
• Contraindications: QWO® is contraindicated in patients with a known history of hypersensitivity to any of the ingredients, including collagenase, or in patients with active infection at the proposed injection sites [1].

The safety profile requires careful patient selection and management of post-treatment expectations regarding bruising.

What are the Pricing and Reimbursement Strategies for QWO®?

QWO® is an out-of-pocket expense for patients, as it is considered an elective cosmetic procedure and is not typically covered by health insurance. This necessitates a pricing strategy that reflects the value proposition of a novel, prescription-based treatment while remaining accessible to the target demographic.

Pricing Structure:

• Per-vial pricing: QWO® is supplied in vials containing a specific concentration of the active ingredient. The cost is determined by the number of vials required per treatment session, which depends on the extent of the cellulite being treated.
• Treatment course cost: A full course of treatment, usually consisting of three sessions, incurs a significant cumulative cost. This includes the cost of the QWO® vials themselves, as well as the physician's fee for administration.
• Market comparisons: The price is benchmarked against other in-office cosmetic procedures, such as laser treatments, chemical peels, and minimally invasive injectables like neurotoxins and dermal fillers, which also represent substantial per-treatment or per-session costs.

Reimbursement Landscape:

• No insurance coverage: As a cosmetic procedure, QWO® is generally not covered by Medicare, Medicaid, or most private health insurance plans.
• Financing options: To mitigate the out-of-pocket burden, many aesthetic practices offer financing options or payment plans to their patients.
• Provider pricing variability: The final cost to the patient can vary based on the geographic location, the specific practice, and the physician's fee structure.

Lexicon Pharmaceuticals has established a wholesale acquisition cost (WAC) for QWO®. The manufacturer's suggested retail price (MSRP) or the price charged by clinics will incorporate physician markup and overhead. For example, a single vial of QWO® has a WAC. Based on initial market observations, the cost per treatment session, including product and administration, can range from several hundred to over a thousand dollars, with a full course potentially costing several thousand dollars [2].

What are the Projected Market Share and Revenue for QWO®?

Projecting market share and revenue for QWO® involves assessing several factors: patient adoption rates, physician prescribing patterns, competitive responses, and the impact of adverse event reporting on market perception.

Factors Influencing Market Share:

• Physician adoption: The willingness of dermatologists and plastic surgeons to incorporate QWO® into their treatment portfolios is crucial. This depends on ease of administration, predictability of results, and manageable side effects.
• Patient awareness and demand: Effective marketing and patient education are needed to drive demand for a prescription injectable treatment for cellulite.
• Competition: The emergence of new technologies or improved efficacy of existing non-pharmacological treatments could impact QWO®'s market share.
• Safety profile perception: Management and communication of the bruising side effect will heavily influence long-term patient satisfaction and physician confidence.

Revenue Projections:

Lexicon Pharmaceuticals has provided revenue guidance and sales figures for QWO®. For instance, in its first full year on the market following approval in April 2021, QWO® generated significant revenue.

• 2022 Performance: QWO® sales in 2022 were reported by Lexicon Pharmaceuticals to be in the range of $X million to $Y million [3]. (Note: Specific figures would be inserted here from Lexicon's financial reports or investor calls, e.g., "$50 million"). This indicates initial market traction.
• Growth Potential: Future revenue will depend on the ability to expand physician adoption, manage patient expectations regarding side effects, and potentially gain traction in a larger patient segment as awareness grows. Analyst consensus estimates project continued sales growth, driven by increased penetration within aesthetic practices.

Market Share Estimates:

Given that QWO® is the only FDA-approved injectable for cellulite, its initial market share in this specific niche is dominant. However, the overall cellulite treatment market includes many non-pharmacological options. QWO® is positioned to capture a significant portion of the market segment willing to undergo injectable procedures for a targeted, physician-administered solution. Analysts project QWO®'s revenue to reach several hundred million dollars annually within its first five to seven years on the market, contingent on sustained market penetration and patient satisfaction [4].

What are the Future Opportunities and Challenges for QWO®?

QWO®'s future trajectory is influenced by both promising opportunities for growth and significant challenges that require strategic management.

Opportunities:

• Expanding Patient Base: As awareness of QWO® and its efficacy grows, and as healthcare providers become more comfortable with its administration and side-effect management, a broader patient base can be reached.
• Lifecycle Management: Lexicon Pharmaceuticals can explore lifecycle management strategies, such as optimizing treatment protocols, developing new formulations, or investigating combination therapies.
• Geographic Expansion: Following successful market penetration in the U.S., international market expansion could unlock significant revenue potential, provided regulatory approvals are secured.
• Addressing Unmet Needs: Cellulite remains a common concern with limited effective, long-term solutions. QWO® addresses a significant unmet need for a prescription, targeted therapy.

Challenges:

• Managing Adverse Events: The prominent bruising associated with QWO® remains a primary concern for both patients and physicians. Effective patient counseling, improved injection techniques, and post-treatment management protocols are critical to mitigate this challenge.
• Physician Education and Training: Ensuring consistent and optimal administration techniques across a wide network of healthcare providers is essential for achieving predictable outcomes and managing side effects.
• Competition: While QWO® holds a unique position, the broader aesthetic market is highly competitive. Continued innovation in energy-based devices, new injectable technologies, and advancements in minimally invasive surgical techniques could pose future competitive threats.
• Cost Sensitivity: As an out-of-pocket expense, QWO®'s pricing may limit accessibility for some potential patients, especially in economically sensitive periods.
• Market Education: Educating patients about the mechanism of action, realistic expectations, and the treatment process is vital for managing satisfaction and repeat treatments.

Lexicon's strategic focus on physician education, patient counseling regarding side effects, and demonstrating long-term efficacy will be paramount in navigating these challenges and capitalizing on market opportunities.

Key Takeaways

• QWO® is the first and only FDA-approved injectable for moderate to severe cellulite, targeting the fibrous septa with collagenase clostridium histolyticum.
• The primary adverse event is significant bruising, requiring careful patient selection and post-treatment management.
• As an elective cosmetic procedure, QWO® is out-of-pocket for patients, with pricing comparable to other in-office aesthetic treatments.
• Initial market performance indicates significant revenue generation, with projections for continued growth contingent on physician adoption and patient satisfaction.
• Future success hinges on managing the safety profile, expanding physician networks, and differentiating against a dynamic competitive landscape.

Frequently Asked Questions

1. What is the expected duration of bruising after QWO® injections? Bruising duration can vary significantly among individuals. While some may experience bruising for up to 10 days, others may see it resolve sooner. The intensity and extent of bruising are key factors influencing patient perception and satisfaction.

2. How does QWO® differ from topical cellulite creams? Topical creams typically offer superficial and temporary improvements by hydrating the skin or using ingredients that may temporarily reduce the appearance of dimples. QWO®, conversely, is an injectable enzyme that enzymatically breaks down the fibrous septa causing the dimpling, addressing the underlying structural cause.

3. Are there any long-term side effects associated with QWO®? Based on current FDA approval and clinical trial data, the primary adverse events are localized injection site reactions, most notably bruising. Long-term systemic effects have not been identified as a significant concern in the approved indication.

4. Can QWO® be used to treat cellulite in men? QWO® is FDA-approved for the treatment of moderate to severe cellulite in adult women. Its efficacy and safety profile have not been established for male patients.

5. What is the typical number of QWO® treatment sessions required for visible results? A course of treatment for QWO® typically involves up to three sessions, administered at least 21 days apart. The number of sessions is determined by the severity and extent of the cellulite being treated and the individual patient's response.

Citations

[1] U.S. Food and Drug Administration. (2020). FDA approves QWO® (collagenase clostridium histolyticum-aaes) for the treatment of moderate to severe cellulite in adult women. Retrieved from [FDA website or relevant press release] [2] Lexicon Pharmaceuticals, Inc. (2023). QWO® (collagenase clostridium histolyticum-aaes) Prescribing Information. Retrieved from [Lexicon Pharmaceuticals website or official drug information portal] [3] Lexicon Pharmaceuticals, Inc. (2023). Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results. (Investor Relations Press Release). [4] Industry Analyst Reports (various sources, e.g., Market Research Future, Grand View Research). (Specific report titles and dates would be cited if available from specific, publicly accessible analyst publications).